Sage Therapeutics Inc (FRA:SG7)
€ 10.78 0.07 (0.65%) Market Cap: 652.41 Mil Enterprise Value: -3.27 Mil PE Ratio: 0 PB Ratio: 1.01 GF Score: 57/100

SAGE Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 11, 2019 / 03:00PM GMT
Release Date Price: €151.02 (-2.62%)
Salveen Jaswal Richter
Goldman Sachs Group Inc., Research Division - VP

With that, I'm Salveen Richter, Biotechnology Analyst for Goldman. I'm just going to start with the disclosure for the day. We are required to make certain disclosures in public appearances about Goldman Sachs' relationships with companies that we discussed. The disclosures related to investment banking [relate to] compensation (inaudible) of ownership. We're prepared to read aloud disclosures for any issuer upon request. However, these disclosures are available on our most recent (inaudible) reports available to you as clients on our firm's portal.

With that, I am pleased to have the team from Sage. We have Jeff Jonas, CEO; and Kimi Iguchi, CFO. Thank you for joining us this morning.

Questions & Answers

Salveen Jaswal Richter;Jeffrey M. Jonas
Goldman Sachs Group Inc., Research Division - VP;Sage Therapeutics, Inc. - CEO, President

And let's start. You're about to launch your first drug, ZULGRESSO -- ZULRESSO, in postpartum depression.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot